share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

SEC ·  Dec 10, 2024 22:00

Summary by Futu AI

Recursion Pharmaceuticals, Inc. announced that Officer Michael Secora plans to sell 15,000 Class A shares on 12/10/2024, with an estimated market value of $116,324.39. The shares were originally acquired through a stock option exercise on 08/15/2023.This sale is part of a larger trading pattern. Over the past three months, Secora has sold a total of 90,000 shares in six separate transactions, generating gross proceeds of $606,864.38. These sales occurred between 09/10/2024 and 11/13/2024, with each transaction involving 15,000 shares.The planned sale on 12/10/2024 appears to be a continuation of this selling strategy, which was initiated on 03/01/2024 when the trading plan was adopted or instructions were given. This consistent selling pattern suggests a predetermined liquidation strategy rather than a response to specific market conditions.
Recursion Pharmaceuticals, Inc. announced that Officer Michael Secora plans to sell 15,000 Class A shares on 12/10/2024, with an estimated market value of $116,324.39. The shares were originally acquired through a stock option exercise on 08/15/2023.This sale is part of a larger trading pattern. Over the past three months, Secora has sold a total of 90,000 shares in six separate transactions, generating gross proceeds of $606,864.38. These sales occurred between 09/10/2024 and 11/13/2024, with each transaction involving 15,000 shares.The planned sale on 12/10/2024 appears to be a continuation of this selling strategy, which was initiated on 03/01/2024 when the trading plan was adopted or instructions were given. This consistent selling pattern suggests a predetermined liquidation strategy rather than a response to specific market conditions.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.